1. Overall survival (OS) in heterogeneous cancer population (Time Frame - Screening (Visit 1) until the date of death (assessed up to 240 months)): overall survival (OS) in heterogeneous cancer population
2. Change in total number of isolated CTCs (Time Frame - Through study completion, an average of 20 years): Change in total number of isolated CTCs
Secondary outcome:
1. Progression free survival (PFS) (Time Frame - Through study completion, an average of 20 years): progression free survival (PFS) in the different cancer cohorts with different treatment regimes
Blood samples: Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
Samples from tumor draining vessels: In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Circulating Tumor Cells (CTC) in Cancer"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!